Results 11 to 20 of about 14,813,386 (261)
An NK-like CAR T cell transition in CAR T cell dysfunction [PDF]
Cell, 2021 Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell exhaustion in the solid tumor microenvironment. To study dysfunction
Glastad, Karl M +46 more
core +4 more sources
Journal for ImmunoTherapy of CancerBackground CD19-directed cancer immunotherapies, based on engineered T cells bearing chimeric antigen receptors (CARs, CAR-T cells) or the systemic administration of bispecific T cell-engaging (TCE) antibodies, have shown impressive clinical responses in
Manel Juan +23 more
doaj +2 more sources
Pharmacologic Control of CAR T Cells [PDF]
International Journal of Molecular Sciences, 2021 Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors.
Benjamin Caulier +2 more
openaire +4 more sources
The EBMT/EHA CAR-T Cell Handbook [PDF]
, 2022 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying ...
core +1 more source
Improving CAR T-Cell Persistence [PDF]
International Journal of Molecular Sciences, 2021 Over the last decade remarkable progress has been made in enhancing the efficacy of CAR T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in hematological settings, patients that respond to CAR T therapies remain at risk of relapsing due to several factors including poor T-cell expansion and lack of long ...
Violena Pietrobon +5 more
openaire +2 more sources
In Situ Programming of CAR T Cells [PDF]
Annual Review of Biomedical Engineering, 2021 Gene therapy makes it possible to engineer chimeric antigen receptors (CARs) to create T cells that target specific diseases. However, current approaches require elaborate and expensive protocols to manufacture engineered T cells ex vivo, putting this therapy beyond the reach of many patients who might benefit.
Parayath, Neha N., Stephan, Matthias T.
openaire +2 more sources
International Journal of Molecular Sciences, 2020 CAR-T therapy has revolutionized the treatment of select hematological malignancies, namely, acute lymphoblastic leukemia and large B-cell lymphomas [...]
openaire +2 more sources
CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy [PDF]
, 2023 三重大学博士(医学)application/pdfThe benefits of CAR-T therapy could be expanded to the treatment of solid tumors through the use of derived autologous αβ T cell, but clinical trials of CAR-T therapy for patients with solid tumors have so far been disappointing.
Wang, Yizheng
core +1 more source
Biomarker Research, 2017 Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients' or donors' blood.
Cheng Zhang +3 more
openaire +3 more sources